Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...
Source: wallstreet-online.de
